BiotechTube

Emavusertib + Venetoclax + Emavusertib

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myelogenous Leukemia

Conditions

Acute Myelogenous Leukemia, Myelodysplastic Syndrome

Trial Timeline

Jul 6, 2020 → Apr 1, 2026

NCT ID
NCT04278768

About Emavusertib + Venetoclax + Emavusertib

Emavusertib + Venetoclax + Emavusertib is a phase 1/2 stage product being developed by Curis for Acute Myelogenous Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT04278768. Target conditions include Acute Myelogenous Leukemia, Myelodysplastic Syndrome.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04278768Phase 1/2Active

Competing Products

20 competing products in Acute Myelogenous Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Curis

chondrocyte-alginate gel suspensionPhase 3
69
Emavusertib + ZanubrutinibPhase 2
44
CUDC-907Phase 2
44
CA-4948Phase 2
44
Emavusertib + IbrutinibPhase 1/2
33